China: China's Recent Development On Granting Biological Sequence Claims

Last Updated: 9 January 2018
Article by Tao Jiang

Life sciences and biotechnology are widely regarded as one of the most promising frontier technologies for the coming decades. Patent protection is at the core of the business for biotechnology companies, and for them, it is also crucial to understand that there exist strong differences amongst jurisdictions concerning what is considered as patentable subject matter, what disclosure is required, and what claim breath is allowed.

One distinctive feature in biotechnology is to define claims by biological sequences (such as nucleotide sequences, amino acid sequences). In China, however, whether these claims are supported in view of examples provided in the description is a prominent issue. A recent case from Supreme People's Court may shed some lights on the Chinese examination inquiry. This short article discussed the case, as well as Chinese practice.

I. Examination of Biological Sequence Claims in China Has Been Strict

Chinese Patent Law Article 26 (4) prescribes that claims shall be supported by the description and shall define the extent of the patent protection sought for in a clear and concise manner.

With respect to the claim support, Chinese examination and judicial practice impose strict criteria on biological sequence claims, i.e., generally allowing claims that encompass only specifically examples in the description. The underlined rationale is attributed to the assumed low predictability of biotechnology inventions, in other words, technical effects of the claimed inventions are not predictable if they are not confirmed by experimental data. Accordingly, one person skilled in the art would not be able to predict whether all variants within the claim scope would have the same function if the relevant examples are not provided in the description.

In view of the above, the allowed breath of a claim is strictly limited by specific examples in China. Had such patent applications been granted, they might be difficult to enforce as competitors may design around by replacing a few irrelevant nucleotides or amino acids. This practice strongly discourages inventions to be filed in China.

We brief below a retrial case to introduce the latest progress on examination inquiry relating to biological sequence claims.means" under Article 44(1).

II. Supreme People's Court (SPC) Case Opened a Bit for Biological Sequence Claims

On April 24, 2017, SPC issued "the top 10 intellectual property cases of Chinese court in 2016." Among them, there is an invention patent invalidation dispute between the Patent Reexamination Board (PRB) of SIPO, Novozymes AS, and Jiangsu Boli Biological Products Co. Ltd1.

In the retrial judgment, SPC elaborated on how to determine whether the biological sequence claims are supported by the description, and discussed the criteria of granting the patent right for such inventions.

Claims and Focus of Case

Novozymes' Chinese invention patent (CN98813338.5) relates to a thermostable glucoamylase that was isolated, purified and characterized from a strain of Talaromyces emersonii CBS 793.97. Compared with the prior art glucoamylases, the isolated glucoamylase has a very high thermal stability. Therefore, the claimed thermostable glucoamylase is suitable for starch conversion (e.g., for producing glucose from starch), and for use in various processes, in particular the saccharification step in starch convention processes.

During the patent invalidation proceeding,2 the granted claims were amended by the patentee, and the isolated enzyme was defined by the way of (i) "function plus comprising"; (ii) "function plus homology"; (iii) "function plus homology plus source"; and (iv) "function plus comprising plus source" respectively.3

One issue was focused on in the case is whether the claims covering the enzymes are supported by the description. In fact, Example 2 shows that an enzyme having SEQ ID NO: 7 has the desired activity and function, and Examples 8, 9, 11 and 12 show that the polypeptides having SEQ ID NO: 34 also have the same properties. There are three (3) different amino acids between SEQ ID NO: 7 and SEQ ID NO: 34, i.e. SEQ ID NO: 34 is over 99% homologous (1% equivalent to 6 amino acids) to SEQ ID NO: 7.

In other words, the focus becomes: given the fact that the enzyme with SEQ ID NO: 7 and its variant with SEQ ID NO: 34 have the desired activity and function which are confirmed by the experimental data, is it allowable to extend the protection scope of claims to other variants of the enzyme? What kind of manner could be permitted to generalize its variants in the claims?

Claims Defined by"Function Plus Comprising"

This claim definition is typical to define biological sequences, and amended claims 1 and 12 of the patent in dispute are drafted in this manner. Amended claim 1 reads as: An isolated enzyme with glucoamylase activity comprising the full-length sequence shown in SEQ ID NO: 7.

Rejected, Chinese Patent Office, PRB and Courts all agreed upon the unmalleability of this claim definition. In this case, PRB, the first instance court4 and the second instance court5 still took the strict criteria, and concluded that claims 1 and 12, as amended, are not supported by the description because the "comprising" is open-ended, which encompasses numerous sequences possibly having any number and any type of amino acid added at one or both ends of the sequence. As a result, one person skilled in the art would not be able to predict whether all sequences within the claim scope would have the glucoamylase activity, and therefore, claims 1 and 12 are not supported by the description.

Unfortunately, the support issue for claims 1 and 12 was not raised in the retrial procedure, and SPC did not provide their thoughts on this.

Claims Defined by "Function Plus homology"

This claim definition is also typical to define biological sequences, and amended claim 6 of the patent in dispute is drafted in this manner. Amended claim 6 reads as: An isolated enzyme with glucoamylase activity, wherein the homologous enzyme is at least 99% with the full-length sequence shown in SEQ ID NO: 7, and having a pI below 3.5 determined by isoelectrical focusing.

Also rejected, Chinese Patent Office, PRB and Courts all agreed upon the unallowability of this claim definition. In this case, PRB, the first instance court and the second instance court still took the strict criteria, and concluded that claim 6 is not supported by the description, because the claimed enzymes encompass a large number of amino acid sequences. Other than the enzyme having SEQ ID NO: 7 and its variant having SEQ ID NO: 34, one person skilled in the art would not be able to predict whether other homologous sequences also have the glucoamylase activity, and therefore claim 6 is not supported by the description.

Unfortunately, the support issue for claim 6 was not raised in the retrial procedure, and SPC did not provide their thoughts on this.

Claims Defined by "Function Plus Homology Plus Source"

This claim definition is not typical to define biological sequences, and there are no criteria for reference according to the previous examination and trial practice. Amended claims 10 and 11 of the patent in dispute are drafted in this manner. Based on the claim 6, amended claim 10 further defined the enzyme is derived from a strain of the filamentous fungus T. emersonii.

In this case, the different criteria were taken by PRB, the first instance court and the second instance court, and the different conclusions were drawn. After the trial, SPC affirmed the decision from PRB and reasoned that in addition to the homologous character, dependent claims 10 and 11 further define the enzyme species source, which significantly limits the scope of claims. One person skilled in the art would understand species being the basic unit of taxonomy which represents a high degree of similarity to each other, and therefore there would exist only very few variant sequences with very high homology. Together with other limitations defined in claim 6, SPC overturned the decisions from lower courts and concluded claims 10 and 11, as amended, are supported.

Claims Defined by "Function Plus Comprising Plus Source"

This claim definition is not typical to define biological sequences, and there are no criteria for reference according to the previous examination and trial practice either. Amended claims 13 and 14 of the patent in dispute are drafted in this manner. In this case, the different criteria were taken by PRB, the first instance court and the second instance court, and the different conclusions were drawn by them. After the trial, SPC affirmed the decision from PRB and reasoned that although the term "comprising" is used, the functional character for having the glucoamylase activity as well as the enzyme species source are also recited. For the person skilled in the art, only very few DNA sequences comprising the sequence (a) or (b) could be obtained from the T.emersonii strain. Accordingly, SPC concluded that the technical solutions refer to claim 12 (a) and (b) in the claims 13 and 14 are supported by the description.

III. Our Practice Tips Relating to Reasonable Protection for Biological Sequence Inventions

Article 26 (4) of the Patent Law is intended to provide the inventor a reasonable protection commensurate in scope with his contribution to the art. This article is basically the same as the PCT which prescribes claims shall be fully supported by the description. Permission to generalize a biological sequence claim reasonably not only meets the legislative intent of Article 26 (4), but also promotes the technological innovation and development in the biotechnology field.

New Trends for Biological Sequence Claims

During the retrial procedure of the above-discussed case, SPC denied the strict criteria taken by lower courts, and articulated judgment rules and granting criteria for the biological sequence claims. That is the claims defined in the homology plus source and function manner are supported by the description, which is instructive for the drafting, examination and trial for the biological sequence related patent applications.

Accordingly, the protection scope is still limited for the applicants and patentees of the biotechnology field, but it has shown that the criteria for examination and trial of the biological sequence claims in China have begun to become more rational.

Strategies for drafting the Biological Sequence Related Invention

From the above case, it can be seen that the examination and trial criteria for the biological sequence claims in China are still rather strict.

Accordingly, in order to get the more reasonable protection scope, the applicants should draft the claims using as many as possible defined manners. In addition to the above-mentioned four manners, "the combination of the terms 'substitution, deletion or addition' plus functions" and "the combination of the terms 'hybridize under stringent conditions' plus functions" could be taken for claim drafting Furthermore, if a gene, polypeptide or protein could not be described by the above-mentioned manners, the physiochemical properties of the polypeptide or protein and the process for processing the gene, polypeptide or protein could be used by the applicants to draft the claims too.

As we all know, biotechnology is an experimental science, and it is unpredictable for its experimental results in some cases. Therefore, for the person skilled in the art, it is very helpful to describe the background art (such as the gene homologous evolutions, the research and development of the related variants, etc.) in the description in detail. Furthermore, in order to get relatively broad protection scope, at the time of drafting the patent applications related to the biological sequences, as many as possible actual examples should be provided in the description to describe the variants' functions and effects, so that the reasonable expectation for the variants could be made by the examiner based on these experimental data and the gene homologous evolutions between different strains or species.

In addition, in order to support the claims sufficiently, it is better to describe the origin of the biological sequences, the technical means for getting them, and their functions and technical effects when drafting the patent application documents. Especially, it is necessary to describe the relationship between the biological sequences and their functions as much as possible, for example, introducing and verifying the functional and structural domains for the biological sequences in the examples, so that the examiner would understand the whole invention and creation, the key sections for the sequence, and the important functions for the variants better in this way, which will be helpful to acquire reasonable protection scope.

In summary, the retrial judgment made by SPC shows the possibility that biological sequence claims are reasonably protected in China. The applicants should pay more attention when drafting the patent application documents, describe the relationship between the biological sequences and their functions, provide enough examples to describe the variants' functions and effects, and draft the claims using as many as possible defined manners, so that the reasonable protection scope could be granted.

Footnotes

1. Decision No. 85: Supreme People's Court [2016] Retrial Judgment

2. Examination Decision on Request for Invalidation No. 17956

3. Wherein, the "function" means having the glucoamylase activity, the "comprising" means the claim is an open-ended mode, the "homology" means the homologous enzyme of at least 99% with the full-length sequence shown in SEQ ID NO: 7, and the "source" means the enzyme is derived from a strain of the filamentous fungus T. emersonii.

4. Decision No. 2721: Beijing First Intermediate People's Court [2012]

5. Decision No. 3524: Beijing Higher People's court [2014]

Originally published June 2017

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions